Loading company…
VyBio researches and develops drug candidates for oncology and chronic diseases.
Founded in 2018 and based in Hangzhou, China, VyBio Therapeutics conducts drug discovery and development for oncology and chronic diseases. Its pipeline includes candidates in Phase I and Phase II trials, alongside early-stage research and preclinical work. In November 2025, it closed a Series B funding round from Qiming Ventures Partners. The company plans to expand its pipeline and advance clinical programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in